Skip to Main Content

Biotech stocks in 2017 were a lot like toddlers: Lovely, affectionate, and playful, but also cranky, volatile, aggravating.

Big picture: The Nasdaq Biotechnology Index performed essentially in line with the broader markets — not great but certainly not a disaster, especially for a turbulent year during which health care investors seemed to be on constant edge about the next Trump tweet.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!